Powder: -20°C for 3 years | In solvent: -80°C for 1 year
EGFR-IN-73 (Compound 3f) effectively inhibits the prevalent EGFR mutation, EGFR Del19, exhibiting an IC50 value of 119 nM [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | EGFR-IN-73 (Compound 3f) effectively inhibits the prevalent EGFR mutation, EGFR Del19, exhibiting an IC50 value of 119 nM [1]. |
Targets&IC50 | EGFR (L858R):820 nM, EGFR (L858R/T790M):>10 μM, EGFR del19:119 nM, EGFR WT:>10 μM |
In vitro | EGFR-IN-73 (Compound 3f), ranging from 0.01 nM to 10 μM over 72 hours, exhibits low activity against wild-type EGFR and potently binds to EGFR mutants including EGFR d746-750 (Del19), EGFR d747-752/P753S, and EGFR L858R, as well as to a lesser extent with EGFR d752-759 and the oncogenic mutants FLT3 D835Y and FLT3 ITD D835V. The compound demonstrates excellent chemical stability, retaining over 95% under acidic conditions after 3 hours and maintaining above 80% stability at neutral pH 7.4. |
Molecular Weight | 405.81 |
Formula | C19H17ClFN3O4 |
CAS No. | 2857033-34-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
EGFR-IN-73 2857033-34-0 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR inhibitor inhibit